Non-steroidal anti-inflammatory drugs and gastroprotection gap among Family Physicians: Results from a survey

[1]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[2]  Á. Lanas,et al.  Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis , 2011, BMC medicine.

[3]  M. Dougados,et al.  The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel , 2010, Annals of the rheumatic diseases.

[4]  Jeong Wook Kim,et al.  [Guidelines of prevention and treatment for NSAID-related peptic ulcers]. , 2009, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[5]  R. Hunt,et al.  Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks , 2009, Alimentary pharmacology & therapeutics.

[6]  L. Targownik,et al.  Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications , 2008, Alimentary pharmacology & therapeutics.

[7]  R. Jhaj,et al.  Prophylactic use of gastro-protective agents in patients on low-dose aspirin. , 2008, British journal of clinical pharmacology.

[8]  M. A. van de Laar,et al.  Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. , 2007, International journal of clinical pharmacology and therapeutics.

[9]  Rute M. Ferreira.  Consumo crónico de medicamentos na população de um centro de saúde , 2007 .

[10]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[11]  L. Targownik,et al.  Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. , 2006, Canadian family physician Medecin de famille canadien.

[12]  R. Hunt,et al.  Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  Á. Lanas,et al.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations , 2006, Gut.

[14]  W. Chey,et al.  Primary care physician perceptions of non‐steroidal anti‐inflammatory drug and aspirin‐associated toxicity: results of a national survey , 2006, Alimentary pharmacology & therapeutics.

[15]  J. McBride,et al.  Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events. , 2005, Rheumatology.

[16]  Peter J. Richardson,et al.  National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. , 2005, Gastroenterology.

[17]  A. Price-Forbes,et al.  A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. , 2005, Rheumatology.

[18]  R. Huupponen,et al.  Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs , 2005, European Journal of Clinical Pharmacology.

[19]  R. Hunt,et al.  Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori--an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[20]  A. Carvajal,et al.  Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study , 2004, European Journal of Clinical Pharmacology.

[21]  L. Laine,et al.  Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy , 2004, Alimentary pharmacology & therapeutics.

[22]  J. Dieleman,et al.  Underutilization of preventive strategies in patients receiving NSAIDs. , 2003, Rheumatology.

[23]  W. Ray,et al.  Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. , 2002, Arthritis and rheumatism.

[24]  A. Majeed,et al.  Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects , 2002, Gut.

[25]  M. Bardou,et al.  Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice , 2001, European Journal of Clinical Pharmacology.

[26]  A. D. Medeiros,et al.  Terapêutica em cuidados de saúde primários numa população rural do distrito de Faro. , 2000 .

[27]  F. Lanza.  A guideline for the treatment and prevention of NSAID-induced ulcers , 1998, American Journal of Gastroenterology.

[28]  D. McDevitt,et al.  General Practitioners' Use of Non-Steroidal Anti-Inflammatory Drugs in Tayside and Fife Regions , 1992, Journal of the Royal Society of Medicine.

[29]  Guilherme Macedo,et al.  Hemorragia digestiva alta associada ao consumo de ácido acetilsalicílico e de anti-inflamatórios não-esteróides em Portugal Resultados do estudo PARAINES Upper gastrointestinal bleeding associated with acetylsalicylic acid and non-steroidal antiinflammatory drugs in Portugal Results from PARAINES st , 2010 .

[30]  M. Bardou,et al.  Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. , 2001, European Journal of Clinical Pharmacology.

[31]  O. Jolobe.  General practitioners' use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. , 1992, Journal of the Royal Society of Medicine.